Category: Business

R-Tech Ueno: Announcement on Collaborative Development of Therapeutic Agent for Diabetic Retinopathy and Diabetic Macular Edema Utilizing VAP-1 Inhibitor (RTU-1096) with Hokkaido University

TOKYO–(BUSINESS WIRE)–R-Tech Ueno (JASDAQ:4573) R-Tech Ueno, Ltd. has announced plans to conduct collaborative research with a group led by Professor Susumu Ishida and Associate Professor Kousuke Noda of the Department of Ophthalmology, Graduate Scho…

Acucela Announces Publication of Pre-clinical Data for Emixustat Hydrochloride

SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced the publication of pre-clinical data related to the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal PLOS ONE. The published article, “Visual Cycle Modulation as an Approach Towa

Second Sight Reports First Quarter 2015 Financial Results

SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today reported financial results for the three-month period ended March 31, 2015. Company Highlights Successfully implanted 19 Argus® II systems in the first quarter of 2015, the highest number for any quarter to date; Net revenue increased 159% to $1.7 millio

Paragon BioTeck Enters Promotional Agreement to Expand Availability of ilast® Portfolio of Products

PORTLAND, Ore.–(BUSINESS WIRE)–Paragon BioTeck, Inc., a privately-held pharmaceutical and medical device company, announced today that it has entered into a multi-year agreement with global healthcare supplier Perrigo Company plc to promote the ilast® range of products for eyelid hygiene in the United States. “The ilast® brand is an integral part of our portfolio of branded products,” said Patrick Witham, President and CEO of Paragon BioTeck, Inc. “By expanding our promotional efforts to incl

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel’s Office of the Chief Scientist

ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2015 of 6.24 million shekels (approximately $1.61 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency. Cell Cure

ISG Secures £4.5 Million Eye Hospital in Central London

LONDON–(BUSINESS WIRE)–ISG has commenced work on a £4.5 million project to create a state-of-the-art eye hospital in London’s renowned Marylebone medical district, for high-end ophthalmic specialist Optegra. The scheme involves the conversion of two period properties in Queen Anne Street into an advanced facility for the treatment of a comprehensive range of eye conditions. Retaining the attractive Edwardian and Victorian façades of the two buildings, ISG will rationalise and unify space and

FibroGen Announces First Quarter 2015 Financial Results

SAN FRANCISCO–(BUSINESS WIRE)–FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the quarter ended March 31, 2015. “FibroGen and its partners, AstraZeneca and Astellas, continue to make excellent progress in the global development of roxadustat for the treatment of anemia in patients with chronic kidney disease,” said Thomas B. Neff, chief executive officer of FibroGen. “Patient enrollment in the seven Phase 3 studies re

Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to be a Featured Speaker at The Common Good Forum

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Robert Lanza, M.D., will be a featured speaker at The Common Good Forum “Venture Economics, Public Policy & Investment: Our Nation’s Future” on May 14, 2015, at the Waldorf Astoria in New York City. “Dr. Lanza’s pioneering research is providing hope for millions of people who may one day benefit from breakthrough c

BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the first quarter ended March 31, 2015 and provided a corporate update. “BioTime continues to advance its strategic product development programs. We are currently enrolling patients in a pivotal trial of Renevia™ for the treatment of HIV-associated lipoatrophy,” said Dr. Michael D. West, BioTime’s Chief Executive Officer. “At this year’s annual meeting of the American Association for Cancer Resea